Clin2
NCT06072612Possibly a fitRecruiting

Bria-IMT plus CPI vs standard care for advanced breast cancer

Breast CancerMetastatic Breast CancerBreast NeoplasmBreast Cancer MetastaticEnd Stage Cancer

Treatments studied

Part of Cancer, Skin clinical trials.

This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
404 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have advanced breast cancer that has spread or come back and cannot be removed with surgery, and you have already tried the recommended treatments for your cancer type.
  • You are expected to live at least 4 more months.
  • You are able to do daily activities with little or no help (ECOG score 0-2).
  • You do not have serious health issues like heart disease, uncontrolled infections, or recent major surgery that would make the trial unsafe.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06471673Recruiting· Phase 1/Phase 2
BRIA-OTS cellular immunotherapy for metastatic breast cancer

This study tests an investigational cellular immunotherapy called BRIA-OTS for people with metastatic breast cancer that has spread and is no longer responding to standard treatments. It aims to help the immune system fight cancer cells.

Santa Monica, California
NCT06959537Recruiting· Phase 1
Combination drug therapy for triple negative breast cancer

This trial tests a new combination of three drugs (cyclophosphamide, axatilimab, and retifanlimab) for people with metastatic triple negative breast cancer. The goal is to see if adding a low dose of chemotherapy can make the immunotherapy work better.

Houston, Texas
NCT06827236Recruiting· Phase 1/Phase 2
Testing a new combination treatment for advanced breast cancer

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.

Beverly Hills, California
NCT06342037Recruiting· Phase 2
New immunotherapy options for advanced triple-negative breast cancer

This trial tests two immunotherapy drugs (atezolizumab and tiragolumab) for people with advanced triple-negative breast cancer that has not responded to standard treatments. It aims to see if this combination can shrink or slow the cancer.

Amsterdam, North Holland
NCT03424005Recruiting· Phase 1/Phase 2
Testing new drug combinations for advanced breast cancer

This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.

Duarte, California
NCT01042379Recruiting· Phase 2
Adaptive drug trial for newly diagnosed breast cancer

This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).

Birmingham, Alabama

Hear when a new Breast cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.